Network-guided sparse learning for predicting cognitive outcomes from MRI measures

Alzheimer's disease (AD) is characterized by gradual neurodegeneration and loss of brain function, especially for memory during early stages. Regression analysis has been widely applied to AD research to relate clinical and biomarker data such as predicting cognitive outcomes from MRI measures. In particular, sparse models have been proposed to identify the optimal imaging markers with high prediction power. However, the complex relationship among imaging markers are often overlooked or simplified in the existing methods. To address this issue, we present a new sparse learning method by introducing a novel network term to more flexibly model the relationship among imaging markers. The proposed algorithm is applied to the ADNI study for predicting cognitive outcomes using MRI scans. The effectiveness of our method is demonstrated by its improved prediction performance over several state-of-the-art competing methods and accurate identification of cognition-relevant imaging markers that are biologically meaningful

Getting the best outcomes from epilepsy surgery.

Neurosurgery is an underutilized treatment that can potentially cure drug-refractory epilepsy. Careful, multidisciplinary presurgical evaluation is vital for selecting patients and to ensure optimal outcomes. Advances in neuroimaging have improved diagnosis and guided surgical intervention. Invasive electroencephalography allows the evaluation of complex patients who would otherwise not be candidates for neurosurgery. We review the current state of the assessment and selection of patients and consider established and novel surgical procedures and associated outcome data. We aim to dispel myths that may inhibit physicians from referring and patients from considering neurosurgical intervention for drug-refractory focal epilepsies. Ann Neurol 2018;83:676-690

Mining brain imaging and genetics data via structured sparse learning

Indiana University-Purdue University Indianapolis (IUPUI)Alzheimer's disease (AD) is a neurodegenerative disorder characterized by gradual loss of brain functions, usually preceded by memory impairments. It has been widely affecting aging Americans over 65 old and listed as 6th leading cause of death. More importantly, unlike other diseases, loss of brain function in AD progression usually leads to the significant decline in self-care abilities. And this will undoubtedly exert a lot of pressure on family members, friends, communities and the whole society due to the time-consuming daily care and high health care expenditures. In the past decade, while deaths attributed to the number one cause, heart disease, has decreased 16 percent, deaths attributed to AD has increased 68 percent. And all of these situations will continue to deteriorate as the population ages during the next several decades. To prevent such health care crisis, substantial efforts have been made to help cure, slow or stop the progression of the disease. The massive data generated through these efforts, like multimodal neuroimaging scans as well as next generation sequences, provides unprecedented opportunities for researchers to look into the deep side of the disease, with more confidence and precision. While plenty of efforts have been made to pull in those existing machine learning and statistical models, the correlated structure and high dimensionality of imaging and genetics data are generally ignored or avoided through targeted analysis. Therefore their performances on imaging genetics study are quite limited and still have plenty to be improved. The primary contribution of this work lies in the development of novel prior knowledge-guided regression and association models, and their applications in various neurobiological problems, such as identification of cognitive performance related imaging biomarkers and imaging genetics associations. In summary, this work has achieved the following research goals: (1) Explore the multimodal imaging biomarkers toward various cognitive functions using group-guided learning algorithms, (2) Development and application of novel network structure guided sparse regression model, (3) Development and application of novel network structure guided sparse multivariate association model, and (4) Promotion of the computation efficiency through parallelization strategies

Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials

INTRODUCTION: The Alzheimer's Disease Neuroimaging Initiative (ADNI) has continued development and standardization of methodologies for biomarkers and has provided an increased depth and breadth of data available to qualified researchers. This review summarizes the over 400 publications using ADNI data during 2014 and 2015. METHODS: We used standard searches to find publications using ADNI data. RESULTS: (1) Structural and functional changes, including subtle changes to hippocampal shape and texture, atrophy in areas outside of hippocampus, and disruption to functional networks, are detectable in presymptomatic subjects before hippocampal atrophy; (2) In subjects with abnormal β-amyloid deposition (Aβ+), biomarkers become abnormal in the order predicted by the amyloid cascade hypothesis; (3) Cognitive decline is more closely linked to tau than Aβ deposition; (4) Cerebrovascular risk factors may interact with Aβ to increase white-matter (WM) abnormalities which may accelerate Alzheimer's disease (AD) progression in conjunction with tau abnormalities; (5) Different patterns of atrophy are associated with impairment of memory and executive function and may underlie psychiatric symptoms; (6) Structural, functional, and metabolic network connectivities are disrupted as AD progresses. Models of prion-like spreading of Aβ pathology along WM tracts predict known patterns of cortical Aβ deposition and declines in glucose metabolism; (7) New AD risk and protective gene loci have been identified using biologically informed approaches; (8) Cognitively normal and mild cognitive impairment (MCI) subjects are heterogeneous and include groups typified not only by "classic" AD pathology but also by normal biomarkers, accelerated decline, and suspected non-Alzheimer's pathology; (9) Selection of subjects at risk of imminent decline on the basis of one or more pathologies improves the power of clinical trials; (10) Sensitivity of cognitive outcome measures to early changes in cognition has been improved and surrogate outcome measures using longitudinal structural magnetic resonance imaging may further reduce clinical trial cost and duration; (11) Advances in machine learning techniques such as neural networks have improved diagnostic and prognostic accuracy especially in challenges involving MCI subjects; and (12) Network connectivity measures and genetic variants show promise in multimodal classification and some classifiers using single modalities are rivaling multimodal classifiers. DISCUSSION: Taken together, these studies fundamentally deepen our understanding of AD progression and its underlying genetic basis, which in turn informs and improves clinical trial desig

The white matter connectome as an individualized biomarker of language impairment in temporal lobe epilepsy.

ObjectiveThe distributed white matter network underlying language leads to difficulties in extracting clinically meaningful summaries of neural alterations leading to language impairment. Here we determine the predictive ability of the structural connectome (SC), compared with global measures of white matter tract microstructure and clinical data, to discriminate language impaired patients with temporal lobe epilepsy (TLE) from TLE patients without language impairment.MethodsT1- and diffusion-MRI, clinical variables (CVs), and neuropsychological measures of naming and verbal fluency were available for 82 TLE patients. Prediction of language impairment was performed using a robust tree-based classifier (XGBoost) for three models: (1) a CV-model which included demographic and epilepsy-related clinical features, (2) an atlas-based tract-model, including four frontotemporal white matter association tracts implicated in language (i.e., the bilateral arcuate fasciculus, inferior frontal occipital fasciculus, inferior longitudinal fasciculus, and uncinate fasciculus), and (3) a SC-model based on diffusion MRI. For the association tracts, mean fractional anisotropy was calculated as a measure of white matter microstructure for each tract using a diffusion tensor atlas (i.e., AtlasTrack). The SC-model used measurement of cortical-cortical connections arising from a temporal lobe subnetwork derived using probabilistic tractography. Dimensionality reduction of the SC was performed with principal components analysis (PCA). Each model was trained on 49 patients from one epilepsy center and tested on 33 patients from a different center (i.e., an independent dataset). Randomization was performed to test the stability of the results.ResultsThe SC-model yielded a greater area under the curve (AUC; .73) and accuracy (79%) compared to both the tract-model (AUC: .54, p < .001; accuracy: 70%, p < .001) and the CV-model (AUC: .59, p < .001; accuracy: 64%, p < .001). Within the SC-model, lateral temporal connections had the highest importance to model performance, including connections similar to language association tracts such as links between the superior temporal gyrus to pars opercularis. However, in addition to these connections many additional connections that were widely distributed, bilateral and interhemispheric in nature were identified as contributing to SC-model performance.ConclusionThe SC revealed a white matter network contributing to language impairment that was widely distributed, bilateral, and lateral temporal in nature. The distributed network underlying language may be why the SC-model has an advantage in identifying sub-components of the complex fiber networks most relevant for aspects of language performance

Early Identification of Alzheimer’s Disease Using Medical Imaging: A Review From a Machine Learning Approach Perspective

Alzheimer’s disease (AD) is the leading cause of dementia in aged adults, affecting up to 70% of the dementia patients, and posing a serious public health hazard in the twenty-first century. AD is a progressive, irreversible and neuro-degenerative disease with a long pre-clinical period, affecting brain cells leading to memory loss, misperception, learning problems, and improper decisions. Given its significance, presently no treatment options are available, although disease advancement can be retarded through medication. Unfortunately, AD is diagnosed at a very later stage, after irreversible damages to the brain cells have occurred, when there is no scope to prevent further cognitive decline. The use of non-invasive neuroimaging procedures capable of detecting AD at preliminary stages is crucial for providing treatment retarding disease progression, and has stood as a promising area of research. We conducted a comprehensive assessment of papers employing machine learning to predict AD using neuroimaging data. Most of the studies employed brain images from Alzheimer’s disease neuroimaging initiative (ADNI) dataset, consisting of magnetic resonance image (MRI) and positron emission tomography (PET) images. The most widely used method, the support vector machine (SVM), has a mean accuracy of 75.4 percent, whereas convolutional neural networks(CNN) have a mean accuracy of 78.5 percent. Better classification accuracy has been achieved by combining MRI and PET, rather using single neuroimaging technique. Overall, more complicated models, like deep learning, paired with multimodal and multidimensional data (neuroimaging, cognitive, clinical, behavioral and genetic) produced superlative results. However, promising results have been achieved, still there is a room for performance improvement of the proposed methods, providing assistance to healthcare professionals and clinician

Towards Precision Psychiatry: gray Matter Development And Cognition In Adolescence

Precision Psychiatry promises a new era of optimized psychiatric diagnosis and treatment through comprehensive, data-driven patient stratification. Among the core requirements towards that goal are: 1) neurobiology-guided preprocessing and analysis of brain imaging data for noninvasive characterization of brain structure and function, and 2) integration of imaging, genomic, cognitive, and clinical data in accurate and interpretable predictive models for diagnosis, and treatment choice and monitoring. In this thesis, we shall touch on specific aspects that fit under these two broad points. First, we investigate normal gray matter development around adolescence, a critical period for the development of psychopathology. For years, the common narrative in human developmental neuroimaging has been that gray matter declines in adolescence. We demonstrate that different MRI-derived gray matter measures exhibit distinct age and sex effects and should not be considered equivalent, as has often been done in the past, but complementary. We show for the first time that gray matter density increases from childhood to young adulthood, in contrast with gray matter volume and cortical thickness, and that females, who are known to have lower gray matter volume than males, have higher density throughout the brain. A custom preprocessing pipeline and a novel high-resolution gray matter parcellation were created to analyze brain scans of 1189 youths collected as part of the Philadelphia Neurodevelopmental Cohort. This work emphasizes the need for future studies combining quantitative histology and neuroimaging to fully understand the biological basis of MRI contrasts and their derived measures. Second, we use the same gray matter measures to assess how well they can predict cognitive performance. We train mass-univariate and multivariate models to show that gray matter volume and density are complementary in their ability to predict performance. We suggest that parcellation resolution plays a big role in prediction accuracy and that it should be tuned separately for each modality for a fair comparison among modalities and for an optimal prediction when combining all modalities. Lastly, we introduce rtemis, an R package for machine learning and visualization, aimed at making advanced data analytics more accessible. Adoption of accurate and interpretable machine learning methods in basic research and medical practice will help advance biomedical science and make precision medicine a reality

Identification of discriminative imaging proteomics associations in Alzheimer's Disease via a novel sparse correlation model

Brain imaging and protein expression, from both cerebrospinal fluid and blood plasma, have been found to provide complementary information in predicting the clinical outcomes of Alzheimer's disease (AD). But the underlying associations that contribute to such a complementary relationship have not been previously studied yet. In this work, we will perform an imaging proteomics association analysis to explore how they are related with each other. While traditional association models, such as Sparse Canonical Correlation Analysis (SCCA), can not guarantee the selection of only disease-relevant biomarkers and associations, we propose a novel discriminative SCCA (denoted as DSCCA) model with new penalty terms to account for the disease status information. Given brain imaging, proteomic and diagnostic data, the proposed model can perform a joint association and multi-class discrimination analysis, such that we can not only identify disease-relevant multimodal biomarkers, but also reveal strong associations between them. Based on a real imaging proteomic data set, the empirical results show that DSCCA and traditional SCCA have comparable association performances. But in a further classification analysis, canonical variables of imaging and proteomic data obtained in DSCCA demonstrate much more discrimination power toward multiple pairs of diagnosis groups than those obtained in SCCA